NextPharma Deal Next Step Toward US Distribution of Epigenomics' Colon Cancer Dx
October 07, 2010
NextPharma Deal Next Step Toward US Distribution of Epigenomics' Colon Cancer Dx
Germany's Epigenomics and life science outsourcing firm NextPharma have signed a global manufacturing contract covering Epi proColon, Epigenomics' nucleic acid amplification-based colorectal cancer screening test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Dx Focus: Diagnovus Engauge-Cancer-DLBCL; Epigenomics Epi ProColon
February 21, 2013 / PCR Insider - Qiagen Building Sample-Prep Tech for Colorectal Cancer Test Under Epigenomics Option
March 3, 2011 / PCR Insider - Epigenomics Taps Pronto Diagnostics as Israeli Distributor for Colorectal Cancer Dx
October 14, 2010 / PCR Insider - NextPharma to Manufacture Epigenomics' Colon Cancer Test
October 6, 2010 / GenomeWeb Daily News - ARUP Launches Blood-Based LDT for Colorectal Cancer in US Based on Epigenomics' Septin9 Biomarker
July 22, 2010 / PCR Insider